AIS Biotech
AIS Biotech is a privately held Grenoble-based biotech developing glycomimetic-based anti-infectives, with lead candidate GlycoFlu, a universal nasal spray for influenza prevention positioned as a complement to vaccines for general consumers and healthcare providers.
- Company typePrivate
- Founded2023
- HeadquartersGrenoble, France
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
AIS Biotech firmographics
Firmographics- Name
- AIS Biotech
- Website
- https://ais-biotech.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AIS Biotech is a privately held Grenoble-based biotech developing glycomimetic-based anti-infectives, with lead candidate GlycoFlu, a universal nasal spray for influenza prevention positioned as a complement to vaccines for general consumers and healthcare providers.
- Ownership category
- akta.pro rank
AIS Biotech industry classification
Industry- Product category
- Antiviral Pharmaceuticals / Anti-Infective Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where AIS Biotech is headquartered
LocationHeadquarters
- HQ city
- Grenoble
- HQ country
- France
- HQ region
- Europe
Markets served
AIS Biotech business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- GlycoFlu Product Sales: Revenue from sale of GlycoFlu universal nasal spray product, positioned as a complementary solution to traditional influenza vaccines
Go-to-market motion1 record
AIS Biotech product offering
Product offeringCore offering
AIS Biotech develops glycomimetic-based anti-infective therapeutics that act as molecular decoys to block pathogen adhesion to host cells, bypassing resistance mechanisms. Its lead commercial product, GlycoFlu, is a universal nasal spray providing broad-spectrum protection against all influenza strains without requiring annual reformulation, positioned as a complement to seasonal vaccines. The pipeline is supported by a scalable, eco-friendly bioproduction platform enabling extension to additional viral and bacterial targets.
Differentiator
Problem solved
Functional benefit
Products and services
- GlycoFlu GlycoFlu is a universal nasal spray anti-infective that uses glycomimetic decoy molecules to prevent pathogen adhesion to host cells, bypassing resistance mechanisms. It is active against all influenza strains without requiring annual adaptation, and is positioned as a complementary solution to traditional influenza vaccines for general consumers and at-risk populations.
- Bioproduction Platform A scalable and environmentally sustainable bioproduction platform used to manufacture glycomimetic anti-infective compounds, enabling cost-effective green production and supporting expansion of the pipeline into additional viral and bacterial targets beyond influenza.
Quantifiable outcome
- Universal protection against all influenza strains without annual adaptation
Companies that use AIS Biotech
Customer profileSegments2 records
Ideal customer profiles2 records
AIS Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AIS Biotech competitors and assessment
Company assessmentEmerging players
- FluGen: Clinical-stage developer of an intranasal M2SR influenza vaccine; directly comparable mucosal-delivery flu-prevention program targeting universal strain coverage.
- Vaxart: Developing oral influenza vaccine alternatives to injectable shots; same needle-free, mucosal-immunity thesis as AIS Biotech's intranasal GlycoFlu, though Vaxart uses a vaccine mechanism.
Broad incumbents
- Sanofi Pasteur: One of the world's largest seasonal influenza vaccine manufacturers; relevant incumbent for GlycoFlu's positioning as a universal complement to traditional flu shots.
- Moderna: Pursuing mRNA-based seasonal and pandemic influenza vaccines; a future standard-of-care threat if strain-matched mRNA flu shots displace the unmet need GlycoFlu is built around.
- GSK: Major influenza vaccine producer with broad respiratory anti-infective portfolio; sets the standard-of-care bar that GlycoFlu must differentiate against.
- AstraZeneca (FluMist): Markets FluMist, the only widely available intranasal influenza vaccine, making it the most directly comparable intranasal flu-prevention product even though delivered via LAIV rather than glycomimetic decoy.
Direct peers
- Fimbrion Therapeutics: Develops mannoside-based anti-adhesion small molecules to prevent bacterial (notably E. coli) attachment to host cells; the closest mechanistic comparable to AIS Biotech's glycomimetic decoy approach, focused on anti-infective indications.
- GlycoMimetics (Pfizer): Developed small-molecule glycomimetic drugs (selectin antagonists) for hematology/oncology; same glycomimetic drug class as AIS Biotech's core chemistry, making it the most direct technology comparable even though application differs. Acquired by Pfizer in 2022.
Market position
Customer concentration
AIS Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
AIS Biotech leadership team
Management profileNumber of profiles
Profiles2 records
AIS Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AIS Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AIS Biotech
What does AIS Biotech do?
AIS Biotech develops glycomimetic-based anti-infective therapeutics that act as molecular decoys to block pathogen adhesion to host cells, bypassing resistance mechanisms. Its lead commercial product, GlycoFlu, is a universal nasal spray providing broad-spectrum protection against all influenza strains without requiring annual reformulation, positioned as a complement to seasonal vaccines. The pipeline is supported by a scalable, eco-friendly bioproduction platform enabling extension to additional viral and bacterial targets.
Is AIS Biotech a public or private company?
AIS Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AIS Biotech founded?
AIS Biotech was founded in 2023. It employs 1 to 10 people.
Where is AIS Biotech based?
AIS Biotech is headquartered in Grenoble, France, in the Europe region.
How does AIS Biotech make money?
One revenue line is on record: glycoFlu Product Sales.
Who are AIS Biotech's main competitors?
Emerging players on record are FluGen and Vaxart. Broad incumbents are Sanofi Pasteur, Moderna, GSK and AstraZeneca (FluMist). Direct peers are Fimbrion Therapeutics and GlycoMimetics (Pfizer).
Does AIS Biotech have an API?
No public API is recorded for AIS Biotech.
What industry is AIS Biotech in?
AIS Biotech's product category is Antiviral Pharmaceuticals / Anti-Infective Therapeutics. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325412 and its SIC code is 2834.